1. Thapa RK, Kim JO (2023) Nanomedicine-based commercial formulations: current developments and future prospects. J Pharm Investig 53(1):19–33
2. Food and Drug Administration (2022) Final guidance for industry: drug products, including biological products, that contain nanomaterials, April. https://www.fda.gov/media/157812/download. Accessed 21 Aug 2023
3. Food and Drug Administration (2018) Liposome drug products: chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labeling documentation, April. https://www.fda.gov/media/70837/download. Accessed 21 Aug 2023
4. Food and Drug Administration (2022) Draft guidance on doxorubicin hydrochloride, May. https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050718.pdf. Accessed 21 Aug 2023
5. Committee E56 Subcommittees and Standards. https://www.astm.org/get-involved/technical-committees/committee-e56/subcommittee-e56. Accessed 1 Sept 2023